

Cyclic Adenosine Monophosphate Signaling in Inflammatory Skin Disease

Jack Levy^{1#}, Dalee M Zhou^{1#} and Jonathan H Zippin^{2*}

¹Weill Cornell Medical College, New York, New York, USA

²Department of Dermatology, NYPH-Weill Cornell Medical Center, New York, New York, USA

*Corresponding Author: Jonathan Zippin, Professor, Department of Dermatology, NYPH-Weill Cornell Medical Center, 1305 York Avenue, 9th Floor, New York 10021, USA, Tel: 646-962-5511; E-mail: jhzipin@nyp.org

#Authors contributed equally.

Received date: December 12, 2015; Accepted date: January 29, 2016; Published date: January 30, 2016

Copyright: © 2015 Patrice GI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The second messenger cyclic adenosine monophosphate (cAMP) regulates numerous key pathways that impact the immune system. Distinct cellular cAMP signaling pathways can lead to both pro- and anti-inflammatory effects depending upon the cell type. When dysregulated, these cAMP pathways can influence the pathogenesis of inflammatory cutaneous diseases, such as atopic dermatitis and psoriasis. In psoriasis and atopic dermatitis, cAMP and/or its effector proteins (e.g., protein kinase A) are downregulated suggesting that elevation of cAMP might be a therapeutic option. cAMP levels are the result of balance between synthesis by adenylyl cyclases and degradation by phosphodiesterases (PDEs). Pharmacologically inhibiting PDEs represents one effective mechanism to raise intracellular cAMP levels perhaps leading to targeted immune suppression. Several drugs have been developed to target PDEs and while some toxicities (e.g., nausea and emesis) exist these drugs are generally well tolerated. Perhaps the best characterized is Apremilast, a PDE4 specific inhibitor, which has been FDA approved for the treatment of psoriasis and shows great promise as a safe and novel immunosuppressive medication. Following on the heels of Apremilast are numerous oral and topical PDE inhibitors in various stages of clinical trials. In this review, we examine the role of cAMP signaling in inflammatory cutaneous diseases and the development of PDE inhibitors as therapeutics.

Keywords: cAMP; PDE; sAC; tmAC; Apremilast

Abbreviations

AC: Adenylyl Cyclase; **AD:** Atopic Dermatitis; **ADSI:** Atopic Dermatitis Severity Index; **ATF:** Activating Transcription Factor; **cAMP:** Cyclic Adenosine Monophosphate; **CLASI:** Cutaneous Lupus Erythematosus Disease Area and Severity Index; **CREB:** cAMP Response Element-Binding Protein; **DLE:** Discoid Lupus Erythematosus; **DQLI:** Dermatology Life Quality Index; **EASI:** Eczema Area and Severity Index; **EPAC:** Exchange Protein Activated by cAMP; **ICER:** Inducible cAMP Early Repressor; **IFN:** Interferon; **IL:** Interleukin; **MIP:** Macrophage Inflammatory Protein; **LP:** Lichen Planus; **NAPSI:** Nail Psoriasis Severity Index; **NF- κ B:** Nuclear Factor Kappa B; **PASI:** Psoriasis Area and Severity Index; **PDE:** Phosphodiesterase; **PGA:** Physician Global Assessment; **PGE:** Prostaglandin; **PKA:** Protein Kinase A; **PPPGA:** Palmoplantar Psoriasis Physician's Global Assessment; **SAC:** Soluble Adenylyl Cyclase; **SASI:** Sarcoidosis Activity and Severity Index; **SCORAD:** SCORing Atopic Dermatitis; **SPGA:** Static Physician's Global Assessment; **ScPGA:** Scalp Physicians Global Assessment; **Teff cell:** Effector T cell; **tmAC:** Transmembrane Adenylyl Cyclase; **TEWL:** Transepidermal Water Loss; **TLR:** Toll-Like Receptor; **TNF:** Tumor Necrosis Factor; **Treg cell:** Regulatory T cell; **UCR:** Upstream Conserved Region

Introduction

Dysregulated homeostasis of immune responses in the skin is a hallmark of inflammatory skin disease. Disorders such as psoriasis and atopic dermatitis (AD) are characterized by elevated local and

peripheral levels of inflammatory mediators and immune cells, most notably T cells, hence the designation of psoriasis and AD as T-cell-mediated skin diseases. Major advances in our understanding of the underlying cellular and molecular mechanisms of these disease processes have implicated numerous signaling pathways in the regulation of skin immunity. Current pathophysiological paradigms of psoriasis and other inflammatory skin diseases recognize both immune cells and resident keratinocytes as players in the pathogenesis of skin inflammation. In particular, it has become clear that the key immunologic role of epidermal keratinocytes in both the acute and chronic phases of skin inflammation is via cytokine production and surface molecule expression [1-3]. Prominent signaling pathways in inflammatory skin disease include the tumor necrosis factor (TNF) and interferon (IFN) pathways, as well as various interleukin pathways (reviewed in [4]). Much less studied is the potential role of the cyclic adenosine monophosphate (cAMP)-signaling pathway, a pathway with proven roles in resident epidermal and dermal immune cells [5], and defined immunosuppressive and anti-inflammatory actions [6]. In addition, there are numerous reports of altered cAMP activity in psoriasis [7-9] and atopic dermatitis [10-13]. Further elevating the importance of cAMP in psoriasis and AD, clinical trials for the treatment of psoriasis with selective phosphodiesterase (PDE) 4 inhibitors, which act on the cAMP pathway, have demonstrated promising results. Here we review the current evidence for a role of cAMP signaling in the pathogenesis of inflammatory skin disease, focusing on psoriasis and AD. We will also provide an overview of novel PDE4 inhibitors currently in clinical trial for the treatment of inflammatory skin diseases.

The cAMP signaling pathway

cAMP is an almost ubiquitous second messenger that regulates a plethora of cellular functions, from metabolism to cell shape and gene expression [14]. cAMP signals are generated in response to diverse stimuli and transduced by at least three types of cAMP effector proteins in mammalian cells: protein kinase A (PKA), exchange proteins activated by cAMP (EPACs), and cyclic nucleotide gated ion channels [15]. cAMP is produced by two related but distinct classes of adenylyl cyclases (ACs) in mammalian cells, the well-known transmembrane adenylyl cyclases (tmACs) and the more recently identified non-canonical soluble adenylyl cyclase (sAC) [15,16]. tmACs are located exclusively at the plasma membrane and classically stimulated by various G protein-coupled receptors (GPCRs), while sAC is localized throughout the cytoplasm, within the nucleus, and at the mitochondria and centriole and is uniquely regulated by ATP, bicarbonate and calcium [17]. Once generated, regardless of the source, cAMP is readily degraded by a variety of phosphodiesterases (PDEs), which are spatially organized alongside cAMP effectors. In this way, cAMP is generated in distinct intracellular pools in a precisely regulated manner, allowing for distinct microdomains of cAMP signaling cascades across different cell types [18]. Figure 1 illustrates the current understanding of cAMP signaling transduction cascades in mammalian cells.

The actions of cAMP are highly dependent on cell type and signaling context. With the recent discovery of sAC and its wide expression in tissues [16,19], the physiologic scope and complexity of cAMP signaling has only expanded, spurring new interest in yet undiscovered roles of specific cAMP microdomains. Aside from the before mentioned immune cells, cAMP and its effector proteins, as well as major downstream targets such as cAMP response element-binding protein (CREB), also have established roles in different skin cells, including keratinocytes, melanocytes, and fibroblasts [5]. Both atopic dermatitis and psoriasis are characterized by abnormal growth and regulation of these key skin cells [20]. We will now review how cAMP can influence different cells in the skin to influence the pathogenesis of inflammatory diseases.

cAMP Signaling in inflammatory immune responses

The role of T cells in the pathogenesis of inflammatory skin disorders is incontrovertible. In this context, it should be noted that cAMP itself plays a direct and crucial role in inflammatory pathways through T cells and other immune cells. In T cells and other types of immune cells, elevated intracellular cAMP concentration suppresses the production of various pro-inflammatory mediators [21], including TNF- α [22], IFN- β [23] and - γ [24], interleukin (IL)-12 family cytokines [24-27], inducible nitric-oxide synthase [28], macrophage inflammatory proteins (MIP)-1 α and -1 β [22], leukotriene B₄ [29], while promoting the release of anti-inflammatory mediators, such as IL-10 [30,31] and suppressor of cytokine signaling-3 [23]. As Figure 1 highlights, there are multiple distinct cAMP signaling microdomains in a mammalian cell and it is currently unknown which microdomain plays a driving role in the immunoregulatory effects of cAMP; however, as discussed below, we are aware of PDEs that play a role [30]. These PDEs promote the release of anti-inflammatory mediators, such as IL-10 [30,31]. In relation to inflammatory skin disease, IL-12 and related cytokines, such as IL-23 and IL-27, which are central to the regulation of T cell responses, have been implicated in the pathogenesis of both psoriasis and atopic dermatitis [32,33]. Multiple substances causing an increase in intracellular cAMP, including

cholera toxin [34-37], histamine [38-43], and prostaglandin E₂ [44-48], have demonstrated a potent inhibitive effect on IL-12-family cytokine production by different immune cells. Finally, the immunosuppressive and anti-inflammatory actions of cAMP have also been attributed in part to its inhibitory downstream effects on the function of one of the master regulators of inflammation, Nuclear Factor-kappaB (NF- κ B) [6,49].




Figure 1: Cyclic adenosine 3', 5' monophosphate (cAMP) signaling microdomains. In response to extra- or intracellular signals, cAMP is formed at discrete intracellular compartments or microdomains including the cell membrane, mitochondria and the nucleus. cAMP microdomains contain an adenylyl cyclase, either a transmembrane adenylyl cyclase (tmAC) or the soluble adenylyl cyclase (sAC), that forms cAMP from adenosine triphosphate (ATP); a phosphodiesterases (PDE) that metabolizes cAMP to adenosine monophosphate (AMP); and a cAMP effector protein such as protein kinase A (PKA), exchange protein activated by cAMP (EPAC) and cyclic nucleotide gated channels. tmAC-dependent signal transduction occurs at the cell membrane when (1) a ligand (e.g., epinephrine) binds its receptor (e.g., β -adrenergic G-protein coupled receptor) and (2) the heterotrimeric G-protein activates the tmAC (3) to make cAMP. In intracellular microdomains (4) such as the nucleus and the mitochondria, cAMP is produced by sAC in response to changes in metabolism or pH. In either case, the cAMP signal is terminated when cAMP is catabolized to AMP by a PDE (5). Abbreviations: TCR, T cell receptor; tmAC, transmembrane adenylyl cyclase; sAC, soluble adenylyl cyclase; cAMP, cyclic adenosine monophosphate; ATP, adenosine triphosphate; AMP, adenosine monophosphate; PDE, phosphodiesterase.




Figure 2: Homeostasis and downstream effects of cAMP signaling in immune cells. The actions of cAMP are highly dependent on cell type, initiating stimulus, and target microdomain and effectors. cAMP signaling pathways commonly exert their effects via gene expression. Of particular importance in inflammatory skin disease, increased intracellular cAMP in immune cells induces anti-inflammatory gene expression while suppressing pro-inflammatory gene expression.

Therefore, it is clear that cAMP signaling pathways lead to a combination of pro- and anti-inflammatory processes (Figure 2), and this apparent conflict is best explained by the existence of multiple cAMP microdomains (Figure 1).

cAMP signaling in psoriasis

Psoriasis is a chronic inflammatory skin disorder that affects an estimated 1-3% of the general population. The disease most commonly manifests as raised, well circumscribed, erythematous plaques with adherent silvery scales, but may also have extradermal manifestations, namely arthritis, termed psoriatic arthritis [20,50]. Psoriatic lesions are characterized by epidermal hyperproliferation with premature differentiation of keratinocytes and predominately dermal infiltration of the skin by dendritic cells, macrophages, and T cells [50]. While much about its pathogenesis remains to be elucidated, psoriasis is increasingly understood to arise from disturbances in the complex interplay between keratinocytes and immune cells from a combination of genetic and environmental factors [51].

Reports of abnormal cAMP signaling in psoriasis date back to the early 1970s [7]. However, the role of cAMP signaling in the pathogenesis of psoriasis remains controversial, largely due to conflicting literature surrounding how cAMP signaling influences psoriasis. Initial studies reported a significant decrease in cAMP in psoriatic epidermis when compared to uninvolved and control epidermis [52-54], and that pharmacologic elevation of intracellular cAMP could suppress epidermal proliferation [55-57]. Later investigations, however, were not consistent, with some finding no difference in cAMP levels in psoriatic epidermis compared to normal epidermis [58,59] and still others confirming prior studies that did find a difference. Yet, further studies revealed a difference in responsiveness

to β -adrenergic stimulation between psoriatic and normal epidermis suggestive of aberrant cAMP production [60] and that β -adrenergic rather than prostaglandin (PGE) E2 stimulation [61] was affected. These observations are not limited to β adrenergic signaling; differences in intracellular cAMP accumulation induced by various tmAC agonists (e.g., cholera toxin, forskolin) were also observed in psoriatic versus uninvolved or normal epidermis [62]. In addition, several studies have also reported deficiencies in cAMP effectors, including decreased expression of and cAMP binding to PKA in psoriatic fibroblasts and erythrocytes [9], which appears responsive to retinoid treatment [63,64] and has been hypothesized to result from altered posttranslational modification of PKA [65,66] or oxidative states in these cells [67]. Further, highly decreased binding of cAMP to PKA in erythrocytes was found by one group to be specific for active psoriasis [68].

New insights in the last decade have revealed additional evidence supporting a role for cAMP signaling in psoriasis. In 2005, it was demonstrated that altered expression of c-Jun and JunB, two key keratinocyte transcription factors regulated by CREB, is sufficient to induce a psoriasis-like phenotype in mice [69]. Correspondingly, upregulated levels of both Jun proteins have also been found in lesional psoriatic skin compared with perilesional skin from patient samples [70]. Upstream of the Jun proteins, increased activation of CREB in association with expression and activation of its upstream activators mitogen- and stress-activated protein kinase 1 (MSK1) and 2 (MSK2) have been demonstrated in both lesional psoriatic epidermis and psoriatic keratinocytes, further strengthening the implication of cAMP signaling in psoriasis pathogenesis [71,72].

Of additional note, the discovery of sAC, a largely unexplored player in disease, introduces new potential routes through which cAMP signaling may influence psoriasis. Recent work has revealed striking differences in sAC localization between keratinocytes in normal skin as compared to certain hyperproliferative skin diseases, including psoriasis. While sAC is diffusely cytoplasmic in normal keratinocytes, in psoriasis, sAC was consistently found almost exclusively in the nuclei of keratinocytes concomitantly with phosphorylated (i.e. activated) CREB. Using a model of epithelial differentiation, it was established that nuclear migration of sAC marks the reentry of differentiated cells into the cell cycle [73]. Taken together with the results of previous work that nuclear migration of sAC can activate PKA-dependent CREB phosphorylation [74], these findings support the hypothesis that nuclear sAC may contribute to psoriasis pathogenesis via modulation of gene expression. Given that all previous studies of cAMP signaling in psoriasis were performed using reagents affecting only the tmAC class of ACs, further studies on sAC in psoriasis and other inflammatory skin disorders hold particular promise.

cAMP Signaling in Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by pruritic blisters and/or scaly plaques whose distribution and presentation vary with age. The disease affects 15%-30% of children and 2%-10% adults, and is commonly associated with other atopic conditions, such as allergic rhinitis and asthma. AD usually begins in infancy and early childhood with erythematous, scaly, weeping (acute) and/or crusted (chronic) lesions of the face, scalp, and extensor surfaces. In adolescence and adulthood, lesions tend to involve the flexures, especially the antecubital and popliteal fossae. Histologically, acute lesions reveal epidermal intercellular

edema (spongiosis), as well as dermal perivascular infiltration by lymphocytes, monocytes, macrophages, dendritic cells, and some eosinophils. Lichenified plaques display epidermal thickening and hypertrophy and prominent hyperkeratosis [20,75]. As with psoriasis, both genetic and environmental factors contribute to the development of AD. Both immune dysregulation and epidermal barrier dysfunction have been implicated in AD pathophysiology, where structural and functional abnormalities of the stratum corneum confer greater permeability to allergens, irritants, and infection [75].

Evidence for cAMP signaling involvement in AD is closely associated with data supporting a possible role for adrenergic pathway dysregulation. The first clues to cAMP pathway involvement in AD stem from observations surrounding the pharmacologic hypersensitivity to β -adrenergic blockade seen in atopic patients and animal models of atopy. In 1968, Szentivanyi postulated that the clinical features of atopic diseases, such as the exaggerated activity of arteriolar and pilomotor smooth muscle observed in the skin of AD patients, might be attributed to β -adrenergic hypo-responsiveness due to an inherited or acquired abnormality in the β -adrenergic receptor-AC system [76]. Supporting this theory, subsequent investigations reported increased cutaneous reactivity in immediate hypersensitivity skin tests [77] and to histamine [78] in atopic patients with β -adrenergic stimulation and diminished reactivity with β -adrenergic blockade. Later, however, attention was turned to immune cells, when one group noted decreases in both the rise of intracellular cAMP in and physiologic response of leukocytes from AD patients exposed to β -adrenergic agonists but not PGE1. Of note, the investigators also demonstrated normal elevation in intracellular cAMP in atopic epidermis despite failure to evoke normal inhibition of mitosis of basal cells from AD patients in response to β -adrenergic stimulation [79]. Subsequent work further revealed reduced pharmacologic cAMP responsiveness and abnormally elevated PDE activity in peripheral blood leukocytes and monocytes in AD [10-13, 80, 81], giving rise to alternative immunologic-based hypotheses regarding cAMP signaling involvement in AD pathogenesis. Indeed, pharmacologic PDE inhibition has been found to reduce the abnormal release of key inflammatory mediators in AD, including histamine [82], immunoglobulin E (IgE) [83], IL-4 [84, 85], PGE E2, and IL-10 [85], by atopic leukocytes (Figure 2).

While cAMP dysfunction in immune cells clearly has a role, there is evidence to suggest cAMP signaling in keratinocytes may also play a role in the pathogenesis of AD. Several reports point to altered catecholamine synthesis and degradation in atopic epidermis leading to decreased intraepidermal cAMP and ultimately keratinocyte hyperproliferation [86-88]. In particular, Schallreuter and colleagues observed a significant decrease in the density of β 2 receptors in both keratinocytes and peripheral blood lymphocytes from AD patients [87], leading to the investigation and subsequent discovery of structural and functional alterations of the β 2 receptor associated with a single point mutation found in nine patients with AD [89]. Although continued investigation is necessary to clarify the significance of these findings-along with the role of β -adrenergic signaling in AD-the potential implications are certainly intriguing from a mechanistic and therapeutic standpoint. Overall, the evidence for aberrant β -adrenergic cAMP signaling at the epidermal level in AD is particularly compelling considering the importance of the signaling pathway in keratinocyte proliferation, differentiation, and, importantly, immune function [90]. Moreover, the role of the non-canonical SAC pathway in AD may reveal additional insights into AD pathogenesis.

Phosphodiesterases as therapeutic targets

Since the discovery in 1958 of phosphodiesterases and their role in cyclic nucleotide metabolism, at least 21 phosphodiesterase genes have been identified. Due to the near ubiquitous presence of these key cyclic nucleotide regulators and the importance of cyclic nucleotides (cAMP and cGMP) in numerous biological processes, pharmaceutical companies have developed PDE inhibitors to treat a variety of diseases. Probably the most well-known examples are the drugs that inhibit PDE5, a cGMP-specific PDE, for the treatment of erectile dysfunction [91]. PDE3, a high-affinity enzyme that degrades both cAMP and cGMP, has been targeted for vascular and airway smooth muscle relaxation, inhibition of platelet aggregation, and positive inotropy for the treatment of intermittent claudication and heart failure. While several PDE families exist, only PDE4, PDE7 and PDE8 specifically degrade cAMP. Of these, type-4 phosphodiesterase (PDE4) has demonstrated a significant role in immune activation.

Type 4 Phosphodiesterases and their role in chronic inflammation

Type-4 phosphodiesterases make up a family of at least 35 isozymes coded for by four separate genes sharing a highly conserved catalytic domain and two upstream conserved regions (UCR1 and 2) unique to type-4 PDEs [92,93]. Evidence suggests that as cells differentiate, PDE4 isoform expression also changes. The UCR domains have been shown to both affect enzyme activity and facilitate binding to scaffolding molecules, allowing PDE4 to localize to various parts of the cell [94]. One important example of intracellular organization is in airway epithelial cells where PDE4 isoforms serve as a firewall to prevent cAMP diffusion from apical adenosine A2B receptors [95]. Multiple distinct PDE4 isoforms are used in a cell to generate cAMP microdomains. PDE4D isoform variants PDE4D8 and PDE4D9, as compared to PDE4D5, are associated with either the β 1 or β 2 adrenergic receptor signal transduction pathways, respectively. This latter finding further supports isoform variant localization to highly specific subcellular microdomains [96].

PDE4s are the predominant mechanism for cAMP degradation in a majority of immune cells, including T- and B-lymphocytes, eosinophils, neutrophils, dendritic cells, monocytes and macrophages along with structural cells including keratinocytes, chondrocytes, epithelial and endothelial cells [97-100]. In both Jurkat T-cells and human peripheral blood T-cells, prostaglandin E2 is capable of inducing PDE4 activity with increased transcription of several PDE4 isoforms [101]. PDE4D3 and PDE4D5 are more highly expressed in monocytes, but with differentiation of these cells to macrophages, there is a downregulation of these isoforms, which are replaced by the PDE4B2 and PDE4A10 long isoforms [102]. Several other isoforms of PDE4 are expressed in human circulating CD4+ T-cells in response to anti-CD3 and anti-CD28 antibodies or in monocytes in response to lipopolysaccharide.

More specifically, TCR and CD28 stimulation in human peripheral T-cells has been shown to recruit PDE4A4, PDE4B2, PDE4D1, and PDE4D2 in complex with β -arrestin to oppose TCR-induced cAMP production [103]. A subsequent study showed that PDE4D plays a prominent role in various T-cell functions, and its activity is sufficient to inhibit T-cell proliferation. In contrast, PDE4A or PDE4B seem to have little to no effect on T-cell proliferation [104].

As described above, cyclic AMP is known to play an important role in inflammatory diseases [97]; therefore, elevation of cAMP would be

predicted to have anti-inflammatory effects [6]. Due to their presence in immune cells, the PDE4 family of enzymes represents a potential therapeutic target to induce immune suppression [105-108]. Thus, the PDE4 family of enzymes represents a promising target in the treatment of cutaneous inflammatory conditions [109]. For these reasons, PDE4 inhibitors have been developed for the treatment of atopic dermatitis and psoriasis in addition to a variety of other inflammatory conditions such as psoriatic arthritis [110-112].

A PDE4 inhibitor for the treatment of psoriasis

Of the PDE4 inhibitors developed to treat dermatologic conditions, none is more studied than Apremilast (CC-10004, Otezla). A selective PDE4 inhibitor, apremilast has been shown to block pro-inflammatory cytokines including TNF- α , Interferon- γ , IL-12, IL-17 and IL-23 with a reduction in psoriasiform biology in humans [113]. By binding to the catalytic site and blocking PDE4 mediated enzymatic degradation of cAMP, apremilast leads to increased cAMP mediated PKA activation and subsequent phosphorylation of CREB. Incubation in apremilast also leads to activation of Activating Transcription Factor (ATF)-1 and inhibition of the transcriptional activity of NF- κ B, resulting in alterations in cellular activity downstream of type-4 toll-like receptor (TLR-4) in both T-cells and monocytes [114] (Figure 2).

Three phase III trials have evaluated the safety and efficacy of apremilast compared to placebo. The ESTEEM 1 and ESTEEM 2 trials, two randomized, placebo-controlled trials studying the safety and efficacy of apremilast, studied 844 and 413 patients, respectively, with moderate to severe plaque psoriasis. The patients were included based on a Psoriasis Area and Severity Index (PASI) score \geq 12, a Static Physician's Global Assessment (sPGA) score \geq 3, and a body surface area of \geq 10%. Nail Psoriasis Severity Index (NAPSI), Scalp Physicians Global Assessment (ScPGA) and Palmoplantar Psoriasis Physician's Global Assessment (PPPGA) were also evaluated [115,116].

Results demonstrated significant improvements in achieving a 75% reduction in Psoriasis Area and Severity Index (PASI-75) and a 50% reduction in Psoriasis Area and Severity Index (PASI-50) in both trials with apremilast 30 mg BID ($P < 0.0001$) at the study's primary end point of week 16. In the ESTEEM 1 trial, PASI-75 was achieved in 33.1% of the apremilast 30 mg BID treatment group versus 5.3% of the placebo-treated group.

sPGA of 0-1 was achieved in 21.7% of those receiving apremilast 30 mg BID compared to 3.9% of the group receiving placebo ($P < 0.0001$) [115]. At week 16, the ESTEEM 2 trial showed 28.8% achievement of PASI-75 compared to 5.8% in placebo and 55.5% achievement of PASI-50 compared to 19.7% in placebo. sPGA of 0-1 was achieved in 20.4% receiving drug compared to only 4.4% of patients receiving placebo ($P < 0.0001$) [116].

The phase IIIb LIBERATE trial compared apremilast 30 mg BID to both Etanercept 50 mg QW and placebo in patients with moderate to severe plaque psoriasis. This study supported the efficacy of apremilast in achieving significant improvements in the PASI-75 response in patients receiving either apremilast 30mg BID or etanercept 50mg QW when compared to placebo ($P < 0.0001$). However, no statistically significant differences were seen between the apremilast and etanercept treatment groups. DLQI scores were significantly improved in the first 16 weeks in both the apremilast 30 mg BID (-8.3) and the etanercept 50 mg QW (-7.8) compared to placebo (-3.8) [117]. Current studies are evaluating the safety, tolerability and pharmacokinetics of apremilast in pediatric patients with moderate to

severe plaque psoriasis and apremilast in combination with narrowband UVB in plaque psoriasis [118, 119]. This drug was approved by the FDA for the treatment of both psoriasis and psoriatic arthritis in 2014 following the above phase III clinical trials for psoriasis and psoriatic arthritis [117,120-123].

Adverse effects of Apremilast

Adverse effects of apremilast have been shown to be mild to moderate in severity; with the largest study (ESTEEM) showing the most frequently reported adverse effects to include: diarrhea (18.7%), upper respiratory tract infection (17.8%), nausea (15.3%), nasopharyngitis (13.4%), tension headache (9.6%), and headache (6.5%). Discontinuation rates for diarrhea and nausea were each $< 2\%$ in the apremilast 30 mg BID group through week 51. Weight loss of up to 10% of body weight were reported in 12% of patients treated with apremilast 30 mg BID for psoriasis compared to 5% in placebo treated patients. Though there were no adverse effects reported as a result of the weight loss, two patients cited weight loss as the reason for discontinuing treatment. Monitoring patients for weight loss is recommended while receiving apremilast [124,125]. Serious adverse effects were low and there was no increase in incidence with long-term exposure to the drug [115,116]. Importantly, compared to current biologic treatment of psoriasis and psoriatic arthritis, there does not appear to be an increased risk for tuberculosis reactivation or lymphomas.

PDE4 inhibitors in the treatment of atopic dermatitis

Compared to treatment of psoriasis and psoriatic arthritis, less is known about the effects of PDE4 inhibitors in the treatment of atopic dermatitis (AD). The mainstay of therapy for those at risk for AD or with mild disease has traditionally focused on topical moisturizers and good skin care, as well as avoidance of possible irritants [126]. Those patients in whom first-line treatment fails are often graduated to topical corticosteroids, calcineurin inhibitors or systemic immunomodulatory therapies [127]. Since pruritus is often associated with AD, antihistamines have also been prescribed [128,129].

It has been established that patients with AD have increased intra-lesional PDE activity [130]. And since cAMP elevation would presumably have anti-inflammatory effects, PDE4 inhibition seems a reasonable therapeutic option for AD.

Apremilast

Apremilast has been investigated in two studies as a therapeutic for AD. The first, a 12-week trial of 20 mg apremilast BID in ten patients with AD and/or allergic contact dermatitis, showed the drug was ineffective [131]. A second, prospective trial compared 20 mg apremilast BID for 3 months with a 30 mg BID dose for 6 months' duration and found significant improvements in pruritus, DLQI and EASI in both groups with the 6-month group showing a reduction in EASI score greater than 50%. This makes apremilast comparable to other systemic agents currently used for AD. In this study, the most commonly reported side effect was nausea, which was dose-dependent [132]. Another randomized, double-blind, phase 2 study is currently in its accrual stage and aims to evaluate EASI score improvements at 12 weeks [133].

Boron-Derivatives

Phenoxybenzoxaboroles, a family of novel small molecules with a boron atom in the 5-membered ring of a 6,5-bicyclic molecule, have recently shown promise in micromolar concentrations [134,135]. One such compound, crisaborole (AN2728, Anacor Pharmaceuticals, Inc., Palo Alto, CA), a topical PDE4 inhibitor, has shown anti-inflammatory properties both *in vitro* and *in vivo* [135]. Crisaborole reduces the production of TNF- α . It also inhibits other pro-inflammatory cytokines, such as IL-12 and IL-23 [136]. A recent phase IIA randomized, double-blind, bilateral 6-week study of twice-daily application of crisaborole (2% ointment) versus vehicle control in 25 adults with AD demonstrate a greater decrease in the Atopic Dermatitis Severity Index (ADSI) score for crisaborole-treated lesions as compared to vehicle-treated lesions in 68% of patients, while 20% experienced a greater decrease in ADSI score for those lesions treated with vehicle as opposed to crisaborole ($P=0.017$). Twelve percent of patients had equal decreases in ADSI scores in crisaborole and vehicle treated lesions. A total of 29 adverse effects were reported in 11 of the study's participants, though most were mild. Larger, phase III pivotal trials will aim to assess efficacy and safety of crisaborole [137].

E6005

Another topical PDE4 inhibitor, E6005 (methyl 4-[(3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl)amino]carbonyl]benzoate), was developed as a novel PDE4 inhibitor with topical application. The molecule has demonstrated selective and effective inhibition of PDE4 and prevents the elaboration of proinflammatory cytokines and adhesion molecules in both lymphocytes and monocytes [138]. E6005 has also demonstrated inhibition of hapten-induced scratching in sensitized mice and spontaneous scratching in mice with chronic dermatitis [138-140]. Preliminary studies of 76 subjects in Japan have established safety and tolerability in healthy volunteers as well as patients with AD [140].

LEO 29102

A piclamilast derivative, LEO 29102 (2-[6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy]-N-propylacetamide), a potent and highly selective PDE4 inhibitor suitable for topical application, has reached phase 2 and has demonstrated clinical efficacy in the treatment of atopic dermatitis. It is currently being evaluated as a low-cost, well-tolerated alternative to other PDE4 inhibitors [141].

Roflumilast

When applied topically to chemically induced murine AD models, roflumilast had beneficial effects on intensity scores and dorsal skin thickness [142]. Currently, topical Roflumilast Cream (0.5%) is still being evaluated in clinical trials. A recently completed three-center randomized, double-blind, placebo controlled German study failed to show a statistically significant improvement in SCORing Atopic Dermatitis (SCORAD) or Transepidermal Water Loss (TEWL) values between the group receiving 0.5% Roflumilast Cream compared to vehicle alone. However, patient assessment of pruritus was significantly improved in the 0.5% Roflumilast treated group (-3.05) compared to vehicle treated group (-1.50) on day 15 of the study ($P=0.013$) [143].

Isoxazoline derivatives

Finally, isoxazoline derivatives with dual PDE4/PDE7 inhibitory activity have recently been described in patent applications with efficacy demonstrated *in vitro* and possible utility in the treatment of AD. Other PDE4/PDE7 inhibitors based on heterospirocyclic compounds as well as the structurally related isoxazoline spirocycles diminish TNF- α release *in vivo* and in cell-based cultures respectively [144]. Another group of PDE inhibitors containing fused furane cycles including benzo[4,5]furo[3,2-c]pyridine derivatives (Glenmark Pharmaceuticals S.A. Mumbai, India) and structural analogues (Matrix Laboratories, Ltd., Secunderabad, India) have demonstrated whole-blood TNF- α inhibition [144].

PDE4 inhibitors in other inflammatory skin diseases

Because of the immunosuppressive effects of PDE4 inhibitors, preliminary investigations of potential therapeutic effects of selective PDE4 inhibitors in lichen planus (LP), discoid lupus erythematosus (DLE), and cutaneous sarcoidosis have been conducted. A 2012 pilot study of the PDE4 inhibitor apremilast in 10 patients with moderate to severe LP produced at least a 2-grade improvement in the Physician Global Assessment after 12 weeks of therapy in 3 patients, as well as significant clinical improvement in the other 7 [145], suggesting that further study of cAMP signaling in LP may be warranted. Published the same year, an 8-patient pilot study of apremilast in DLE showed marked reductions in CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) scores in 4 patients who completed the full 85 days of treatment [146]. Finally, a 15-patient study also published in 2012 investigating the efficacy and safety of apremilast in cutaneous sarcoidosis reported statistically significant improvement in both SASI (Sarcoidosis Activity and Severity Index) scores and photographic comparison of cutaneous lesions prior to and after 12 weeks of treatment. Interestingly, 3 patients experienced relapse of cutaneous lesions only partially responsive to prednisone therapy within 3 months of apremilast discontinuation [147].

Other studies have shown apremilast to be effective in the treatment of rosacea with statistically significant improvement on the Physician Global Assessment (PGA) and Physician Overall Erythema Severity, erythematotelangiectatic rating and nontransient erythema [148]. Another case series evaluating apremilast for the treatment of lichen planus demonstrated significant clinical improvement of at least 2-grades in PGA following twelve weeks of treatment with 20 mg apremilast BID [149].

Conclusion

A key second messenger and regulator of numerous inflammatory mediators, cAMP is a prominent player in immune mechanisms underlying inflammatory skin diseases such as psoriasis and atopic dermatitis. Changes in intracellular cAMP via production and/or degradation can profoundly influence immune responses in T cells and other immune cells, where increased cAMP generally suppresses inflammatory mediator production and other immune functions. In a broader cellular context, cAMP plays a pivotal role in cellular proliferation and differentiation as well as gene expression-primary cellular processes whose disruption in skin as well as immune cells may also be involved the pathogenesis of these diseases. The potential significance and contribution of abnormal cAMP signaling in skin cells, especially keratinocytes, in inflammatory skin disorders is far from established but becoming clearer. Regardless, the efficacy of novel

oral and topical PDE4 inhibitors such as apremilast that target cAMP degradation bolsters evidence that cAMP pathways are not only principally involved but also relevant therapeutic targets in these diseases. In addition, the safety and favorable side-effect profiles of this class of drugs makes them particularly attractive for continued development and application in various inflammatory cutaneous diseases. Overall, further studies and a better understanding of cAMP signaling in these diseases are likely to provide new insights into disease pathogenesis as well as other potential therapeutic targets and treatment approaches.

References

1. Pasparakis M, Haase I, Nestle FO (2014) Mechanisms regulating skin immunity and inflammation. *Nat Rev Immunol* 14: 289-301.
2. Gutowska-Owsiak D, Ogg GS (2012) The epidermis as an adjuvant. *J Invest Dermatol* 132: 940-948.
3. Köllisch G, Kalali BN, Voelcker V, Wallich R, Behrendt H, et al. (2005) Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. *Immunology* 114: 531-541.
4. Albanesi C, Pastore S (2010) Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs. *Curr Drug Metab* 11: 210-227.
5. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kausar S, et al. (2006) Corticotropin releasing hormone and the skin. *Front Biosci* 11: 2230-2248.
6. Gerlo S, Kooijman R, Beck IM, Kolmus K, Spooren A, et al. (2011) Cyclic AMP: a selective modulator of NF- κ B action. *Cell Mol Life Sci* 68: 3823-3841.
7. Voorhees JJ, Duell EA (1971) Psoriasis as a possible defect of the adenylyl cyclase-cyclic AMP cascade. A defective chalone mechanism? *Arch Dermatol* 104: 352-358.
8. Wadskov S, Kassis V, Søndergaard J (1979) Cyclic AMP and psoriasis once more. *Acta Derm Venereol* 59: 525-527.
9. Brion DE, Raynaud F, Plet A, Laurent P, Leduc B, et al. (1986) Deficiency of cyclic AMP-dependent protein kinases in human psoriasis. *Proc Natl Acad Sci U S A* 83: 5272-5276.
10. Hanifin JM, Chan SC (1995) Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. *J Invest Dermatol* 105: 84S-88S.
11. Sawai T, Ikai K, Uehara M (1995) Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis. *Br J Dermatol* 132: 22-24.
12. Holden CA (1990) Atopic dermatitis: a defect of intracellular secondary messenger systems? *Clin Exp Allergy* 20: 131-136.
13. Grewe SR, Chan SC, Hanifin JM (1982) Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. *J Allergy Clin Immunol* 70: 452-457.
14. Sutherland EW (1972) Studies on the mechanism of hormone action. *Science* 177: 401-408.
15. Kamenetsky M, Middelhaufe S, Bank EM, Levin LR, Buck J, et al. (2006) Molecular details of cAMP generation in mammalian cells: a tale of two systems. *J Mol Biol* 362: 623-639.
16. Tresguerres M, Levin LR, Buck J (2011) Intracellular cAMP signaling by soluble adenylyl cyclase. *Kidney Int* 79: 1277-1288.
17. Zippin JH, Chen Y, Nahirney P, Kamenetsky M, Wuttke MS, et al. (2003) Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains. *FASEB J* 17: 82-84.
18. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. *Drug Discov Today* 10: 1503-1519.
19. Geng W, Wang Z, Zhang J, Reed BY, Pak CY, et al. (2005) Cloning and characterization of the human soluble adenylyl cyclase. *Am J Physiol Cell Physiol* 288: C1305-1316.
20. Bowcock AM, Cookson WO (2004) The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. *Hum Mol Genet* 13 Spec No 1: R43-55.
21. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M (2008) Cyclic AMP: master regulator of innate immune cell function. *Am J Respir Cell Mol Biol* 39: 127-132.
22. Aronoff DM, Carstens JK, Chen GH, Toews GB, Peters-Golden M (2006) Short communication: differences between macrophages and dendritic cells in the cyclic AMP-dependent regulation of lipopolysaccharide-induced cytokine and chemokine synthesis. *J Interferon Cytokine Res* 26: 827-833.
23. Xu XJ, Reichner JS, Mastrofrancesco B, Henry WL Jr, Albina JE (2008) Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. *J Immunol* 180: 2125-2131.
24. Yao C, Hirata T, Soontrapa K, Ma X, Takemori H, et al. (2013) Prostaglandin E₂ promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase. *Nat Commun* 4: 1685.
25. Feng WG, Wang YB, Zhang JS, Wang XY, Li CL, et al. (2002) cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in murine peritoneal macrophages. *Cell Res* 12: 331-337.
26. Szabo G, Girouard L, Mandrekar P, Catalano D (1998) Regulation of monocyte IL-12 production: augmentation by lymphocyte contact and acute ethanol treatment, inhibition by elevated intracellular cAMP. *Int J Immunopharmacol* 20: 491-503.
27. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA (1995) Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. *J Exp Med* 181: 775-779.
28. Markovic M, Miljkovic Dj, Trajkovic V (2003) Regulation of inducible nitric oxide synthase by cAMP-elevating phospho-diesterase inhibitors. *Curr Drug Targets Inflamm Allergy* 2: 63-79.
29. Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, et al. (2004) Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. *J Biol Chem* 279: 41512-41520.
30. Gasperini S, Crepaldi L, Calzetti F, Gatto L, Berlato C, et al. (2002) Interleukin-10 and cAMP-elevating agents cooperate to induce suppressor of cytokine signaling-3 via a protein kinase A-independent signal. *Eur Cytokine Netw* 13: 47-53.
31. Liopeta K, Boubali S, Virgilio L, Thyphronitis G, Mavrothalassitis G, et al. (2009) cAMP regulates IL-10 production by normal human T lymphocytes at multiple levels: a potential role for MEF2. *Mol Immunol* 46: 345-354.
32. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, et al. (2015) IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. *Nat Med* 21: 719-729.
33. Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, et al. (1998) A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. *Immunol Today* 19: 359-361.
34. la Sala A, He J, Laricchia-Robbio L, Gorini S, Iwasaki A, et al. (2009) Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. *J Exp Med* 206: 1227-1235.
35. Lavelle EC, Jarnicki A, McNeela E, Armstrong ME, Higgins SC, et al. (2004) Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. *J Leukoc Biol* 75: 756-763.
36. Burkart V, Kim YE, Hartmann B, Ghiea I, Sylthath U, et al. (2002) Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. *J Immunol* 168: 1730-1737.
37. Braun MC, He J, Wu CY, Kelsall BL (1999) Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. *J Exp Med* 189: 541-552.

38. Gschwandtner M, Bunk H, Köther B, Thurmond RL, Kietzmann M, et al. (2012) Histamine down-regulates IL-27 production in antigen-presenting cells. *J Leukoc Biol* 92: 21-29.
39. Gutzmer R, Diestel C, Mommert S, Köther B, Stark H, et al. (2005) Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. *J Immunol* 174: 5224-5232.
40. Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, et al. (2001) Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. *J Immunol* 167: 3682-3686.
41. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM (2001) Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. *J Clin Invest* 108: 1865-1873.
42. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, et al. (1998) Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. *J Immunol* 161: 2586-2593.
43. van der Pouw Kraan TC, Snijders A, Boeije LC, de Groot ER, Alewijnse AE, et al. (1998) Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. *J Clin Invest* 102: 1866-1873.
44. Kalim KW, Groettrup M (2013) Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit. *Mol Immunol* 53: 274-282.
45. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, et al. (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. *J Exp Med* 206: 535-548.
46. Walker W, Rotondo D (2004) Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. *Immunology* 111: 298-305.
47. KaliÅ ski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML (2001) Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. *Blood* 97: 3466-3469.
48. Wu CY, Wang K, McDyer JF, Seder RA (1998) Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. *J Immunol* 161: 2723-2730.
49. Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, et al. (2005) Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. *Eur J Immunol* 35: 31-41.
50. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. *N Engl J Med* 361: 496-509.
51. Kim J, Krueger JG (2015) The immunopathogenesis of psoriasis. *Dermatol Clin* 33: 13-23.
52. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell ER (1972) The cyclic AMP system in normal and psoriatic epidermis. *J Invest Dermatol* 59: 114-120.
53. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell ER (1972) Decreased cyclic AMP in the epidermis of lesions of psoriasis. *Arch Dermatol* 105: 695-701.
54. Voorhees JJ, Duell EA, Bass LJ, Powell JA, Harrell ER (1972) The cyclic AMP system in normal and psoriatic epidermis. *J Invest Dermatol* 59: 114-120.
55. Flaxman BA, Harper RA (1975) *In vitro* analysis of the control of keratinocyte proliferation in human epidermis by physiologic and pharmacologic agents. *J Invest Dermatol* 65: 52-59.
56. Harper RA, Flaxman BA (1975) Effect of pharmacological agents on human keratinocyte mitosis *in vitro*. II. Inhibition by catecholamines. *J Cell Physiol* 86: 293-299.
57. Voorhees JJ, Duell EA, Kelsey WH (1972) Dibutyl cyclic AMP inhibition of epidermal cell division. *Arch Dermatol* 105: 384-386.
58. Adachi K, Iizuka H, Halprin KM, Levine V (1980) Epidermal cyclic AMP is not decreased in psoriasis lesions. *J Invest Dermatol* 74: 74-76.
59. Yoshikawa K, Adachi K, Halprin KM, Levine V (1975) Is the cyclic AMP in psoriatic epidermis low? *Br J Dermatol* 93: 253-258.
60. Yoshikawa K, Adachi K, Halprin KM, Levine V (1975) On the lack of response to catecholamine stimulation by the adenylyl cyclase system in psoriatic lesions. *Br J Dermatol* 92: 619-624.
61. Mui MM, Hsia SL, Halprin KM (1975) Further studies on adenylyl cyclase in psoriasis. *Br J Dermatol* 92: 255-262.
62. Iizuka H, Matsuo S, Tamura T, Ohkuma N (1988) Increased cholera toxin-, and forskolin-induced cyclic AMP accumulations in psoriatic involved versus uninvolved or normal human epidermis. *J Invest Dermatol* 91: 154-157.
63. Raynaud F, Leduc C, Anderson WB, Evain-Brion D (1987) Retinoid treatment of human psoriatic fibroblasts induces an increase in cyclic AMP-dependent protein kinase activity. *J Invest Dermatol* 89: 105-110.
64. Raynaud F, Liapi C, Gerbaud P, Anderson WB, Evain-Brion D (1988) Effect of retinoic acid on cAMP dependent protein phosphorylation in psoriatic fibroblasts. *Biochem Biophys Res Commun* 156: 263-268.
65. Tournier S, Raynaud F, Gerbaud P, Lohmann SM, Anderson WB, et al. (1996) Retinoylation of the type II cAMP-binding regulatory subunit of cAMP-dependent protein kinase is increased in psoriatic human fibroblasts. *J Cell Physiol* 167: 196-203.
66. Tournier S, Gerbaud P, Anderson WB, Lohmann SM, Evain-Brion D, et al. (1995) Post-translational abnormality of the type II cyclic AMP-dependent protein kinase in psoriasis: modulation by retinoic acid. *J Cell Biochem* 57: 647-654.
67. Raynaud F, Evain-Brion D, Gerbaud P, Marciano D, Gorin I, et al. (1997) Oxidative modulation of cyclic AMP-dependent protein kinase in human fibroblasts: possible role in psoriasis. *Free Radic Biol Med* 22: 623-632.
68. Schopf RE, Langendorf Y, Benz RE, Färber L, Benes P (2002) A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasis. *J Invest Dermatol* 119: 160-165.
69. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, et al. (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. *Nature* 437: 369-375.
70. Zenz R, Wagner EF (2006) Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. *Int J Biochem Cell Biol* 38: 1043-1049.
71. Funding AT, Johansen C, Kragballe K, Iversen L (2007) Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. *J Invest Dermatol* 127: 2012-2019.
72. Funding AT, Johansen C, Kragballe K, Otkjaer K, Jensen UB, et al. (2006) Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. *J Invest Dermatol* 126: 1784-1791.
73. Zippin JH, Chadwick PA, Levin LR, Buck J, Magro CM (2010) Soluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases. *J Invest Dermatol* 130: 1279-1287.
74. Zippin JH1, Farrell J, Huron D, Kamenetsky M, Hess KC, et al. (2004) Bicarbonate-responsive "soluble" adenylyl cyclase defines a nuclear cAMP microdomain. *J Cell Biol* 164: 527-534.
75. Bieber T (2008) Atopic dermatitis. *N Engl J Med* 358: 1483-1494.
76. Szentivanyi A (1968) The beta adrenergic theory of the atopic abnormality in bronchial asthma. *Journal of Allergy* 42: 203-232.
77. Shereff RH, Harwell W, Lieberman P, Rosenberg EW, Robinson H (1973) Effect of beta adrenergic stimulation and blockade on immediate hypersensitivity skin test reactions. *J Allergy Clin Immunol* 52: 328-333.
78. Lamkin N Jr, Lieberman P, Shereff R, Rosenberg EW, Robinson H (1976) Effect of beta adrenergic stimulation and blockade on cutaneous reactivity to histamine. *J Allergy Clin Immunol* 57: 449-453.
79. Reed CE, Busse WW, Lee TP (1976) Adrenergic mechanisms and the adenylyl cyclase system in atopic dermatitis. *J Invest Dermatol* 67: 333-338.
80. Hanifin JM (1990) Phosphodiesterase and immune dysfunction in atopic dermatitis. *J Dermatol Sci* 1: 1-6.
81. Cooper KD, Chan SC, Hanifin JM (1985) Lymphocyte and monocyte localization of altered adrenergic receptors, cAMP responses, and cAMP

- phosphodiesterase in atopic dermatitis. A possible mechanism for abnormal radiosensitive helper T cells in atopic dermatitis. *Acta Derm Venereol Suppl (Stockh)* 114: 41-47.
82. Butler JM, Chan SC, Stevens S, Hanifin JM (1983) Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. *J Allergy Clin Immunol* 71: 490-497.
83. Cooper KD, Kang K, Chan SC, Hanifin JM (1985) Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells *in vitro*. *J Invest Dermatol* 84: 477-482.
84. Chan SC, Li SH, Hanifin JM (1993) Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. *J Invest Dermatol* 100: 681-684.
85. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, et al. (1996) Type 4 phosphodiesterase inhibitors have clinical and *in vitro* anti-inflammatory effects in atopic dermatitis. *J Invest Dermatol* 107: 51-56.
86. Schallreuter KU, Pittelkow MR, Swanson NN, Beazley WD, Körner C, et al. (1997) Altered catecholamine synthesis and degradation in the epidermis of patients with atopic eczema. *Arch Dermatol Res* 289: 663-666.
87. Schallreuter KU (1997) Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. *J Invest Dermatol Symp Proc* 2: 37-40.
88. Bamshad J (1969) Catechol-O-methyl transferase in skin of patients with atopic dermatitis. *J Invest Dermatol* 52: 100-102.
89. Schallreuter KU, Wei Y, Pittelkow MR, Swanson NN, Gibbons NC, et al. (2007) Structural and functional alterations in the beta2-adrenoceptor are caused by a point mutation in patients with atopic eczema. *Exp Dermatol* 16: 807-813.
90. Martin-Ezquerria G, Man MQ, Hupe M, Rodriguez-Martin M, Youm JK, et al. (2011) Psychological stress regulates antimicrobial peptide expression by both glucocorticoid and beta-adrenergic mechanisms. *Eur J Dermatol* 2: 48-51.
91. Boswell-Smith V, Spina D, Page CP (2006) Phosphodiesterase inhibitors. *Br J Pharmacol* 147: S252-257.
92. Bolger G, Michaeli T, Martins T, St John T, Steiner B, et al. (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of *Drosophila melanogaster* are potential targets for antidepressant drugs. *Mol Cell Biol* 13: 6558-6571.
93. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. *Mol Pharmacol* 50: 891-899.
94. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, et al. (2001) Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. *J Biol Chem* 276: 11189-11198.
95. Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, et al. (2005) Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. *J Biol Chem* 280: 7997-8003.
96. Richter W, Day P, Agrawal R, Bruss MD, Granier S, et al. (2008) Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. *EMBO J* 27: 384-393.
97. Torphy TJ (1998) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. *Am J Respir Crit Care Med* 157: 351-370.
98. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, et al. (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell Signal* 26: 2016-2029.
99. Wright LC, Seybold J, Robichaud A, Adcock IM, Barnes PJ (1998) Phosphodiesterase expression in human epithelial cells. *Am J Physiol* 275: L694-700.
100. Tenor H, Hedbom E, Häuselmann HJ, Schudt C, Hatzelmann A (2002) Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes—functional importance of phosphodiesterase 4. *Br J Pharmacol* 135: 609-618.
101. Seybold J, Newton R, Wright L, Finney PA, Suttorp N, et al. (1998) Induction of Phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in Human Peripheral Blood T-lymphocytes by 8-Bromo-cAMP and Gs-coupled Receptor Agonists: POTENTIAL ROLE IN 2-ADRENORECEPTOR DESENSITIZATION. *Journal of Biological Chemistry* 273: 20575-20588.
102. Shepherd MC, Baillie GS, Stirling DI, Houslay MD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. *Br J Pharmacol* 142: 339-351.
103. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, et al. (2004) TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. *J Immunol* 173: 4847-4858.
104. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C (2007) Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. *J Immunol* 178: 4820-4831.
105. Page CP, Spina D (2011) Phosphodiesterase inhibitors in the treatment of inflammatory diseases. *Handb Exp Pharmacol* : 391-414.
106. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R (2012) Phosphodiesterases as therapeutic targets for Alzheimer's disease. *ACS Chem Neurosci* 3: 832-844.
107. Richter W, Menniti FS, Zhang HT, Conti M (2013) PDE4 as a target for cognition enhancement. *Expert Opin Ther Targets* 17: 1011-1027.
108. Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. *Lancet* 365: 167-175.
109. Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* 69: 249-315.
110. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, et al. (2012) Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheumatism* 64: 3156-3167.
111. Schett G, Sloan VS, Stevens RM, and Schafer P (2010) Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. *Ther Adv Musculoskelet Dis* 2: 271-278.
112. Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M (2007) Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. *Inflamm Allergy Drug Targets* 6: 17-26.
113. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, et al. (2008) An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. *Curr Med Res Opin* 24: 1529-1538.
114. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. *Drug Discov Today* 10: 1503-1519.
115. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, et al. (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *J Am Acad Dermatol* 73: 37-49.
116. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, et al. (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). *Br J Dermatol* 173: 1387-1399.
117. Gooderham M, Papp K (2015) Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. *BioDrugs* 29: 327-339.
118. Clinical trials for apremilast in the treatment of psoriasis.
119. Clinical trials for apremilast in the treatment of psoriasis among pediatric patients.
120. Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, et al. (2013) Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized,

- double-blind, placebo-controlled, parallel-group, dose-comparison study. *J Eur Acad Dermatol Venereol* 27: e376-383.
121. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, et al. (2012) Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. *Lancet* 380: 738-746.
122. Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, et al. (2013) Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. *Health Qual Life Outcomes* 11: 82.
123. Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, et al. (2013) Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. *J Drugs Dermatol* 12: 888-897.
124. Reich K, Sobell J, Stevens RM, Day RM, Shah K (2015) Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: Pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. *Journal of the American Academy of Dermatology* 72: AB227.
125. Celgene Corporation. Otezla (apremilast): full prescribing information.
126. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, et al. (2014) Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol* 71: 116-132.
127. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, et al. (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol* 70: 338-351.
128. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, et al. (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol* 71: 327-349.
129. Darsow U, Pfab F, Valet M, Huss-Marp J, Behrendt H, et al. (2011) Pruritus and atopic dermatitis. *Clin Rev Allergy Immunol* 41: 237-244.
130. Holden CA, Chan SC, Hanifin JM (1986) Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. *J Invest Dermatol* 87: 372-376.
131. Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB (2012) A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. *J Drugs Dermatol* 11: 341-346.
132. Samrao A, Berry TM, Goreshi R, Simpson EL (2012) A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. *Arch Dermatol* 148: 890-897.
133. Clinical trials for apremilast in atopic dermatitis.
134. Freund YR, Akama T, Alley MR, Antunes J, Dong C, et al. (2012) Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. *FEBS Lett* 586: 3410-3414.
135. Akama T, Baker SJ, Zhang Y-K, Hernandez V, Zhou H, et al. (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. *Bioorganic & Medicinal Chemistry Letters* 19: 2129-2132.
136. Freund YR, Akama T, Alley MR, Antunes J, Dong C, et al. (2012) Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. *FEBS Lett* 586: 3410-3414.
137. Murrell DF, Gebauer K, Spelman L, Zane LT (2015) Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study. *J Drugs Dermatol* 14: 1108-1112.
138. Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, et al. (2013) Antipruritic Effect of the Topical Phosphodiesterase 4 Inhibitor E6005 Ameliorates Skin Lesions in a Mouse Atopic Dermatitis Model. *Journal of Pharmacology and Experimental Therapeutics* 346: 105-112.
139. Andoh T, Yoshida T, Kuraishi Y (2014) Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. *Exp Dermatol* 23: 359-361.
140. Ohba F, Nomoto M, Hojo S, Akama H (2015) Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. *J Dermatolog Treat* .
141. Felding J, Sørensen MD, Poulsen TD, Larsen J, Andersson C, et al. (2014) Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis. *J Med Chem* 57: 5893-5903.
142. Heo JY, Cho YS, Cheon HG (2010) Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. *Pharmazie* 65: 906-912.
143. Clinical Trials for Roflumilast in Atopic Dermatitis.
144. Vávrová K (2016) Emerging small-molecule compounds for treatment of atopic dermatitis: a review. *Expert Opin Ther Pat* 26: 21-34.
145. Paul J, Foss CE, Hirano SA, Cunningham TD, Pariser DM (2013) An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. *J Am Acad Dermatol* 68: 255-261.
146. De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr (2012) Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. *J Drugs Dermatol* 11: 1224-1226.
147. Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE (2012) Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. *Arch Dermatol* 148: 262-264.
148. Clinical trials for apremilast in the treatment of rosacea.
149. Clinical trials for apremilast in the treatment of lichen planus.